Close

pCDCAR1 CD20 h(ζ) (CAR-MZ017)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of Recurrent/refractory CD20+ lymphoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Recurrent/refractory CD20+ lymphoma
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • Leu-16
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
FunS

Fig.1 anti-CD20 binding activity of CD20-binding polypeptide compositions and immunocytokines (ICs).

CAR Construction : Latest CAR Construction

Fig.1 anti-CD20 binding activity of CD20-binding polypeptide compositions and immunocytokines (ICs).

Cyt

Fig.2 antibody-dependent cell-mediated and complement-dependent cytotoxicity.

CAR Construction : Latest CAR Construction

Fig.2 antibody-dependent cell-mediated and complement-dependent cytotoxicity.

Panel A: Antibodies tested were 2B8 (filled circles), chLeu16 (filled diamonds), and Leu16VhY/VkZ (anti-CD20 PC1) (open triangles). Panel B: Immunocytokines tested were chLeu16-IL2 (filled squares), and Leu16VhY/VkZ-IL2 (anti-CD20 PC2) (filled triangles), deglycosylated Leu16VhY/VkZ-IL2 (anti-CD20 PC3) (X's), and huKS-IL2 (open circles) as a non-binding control. Panel C shows CDC activity.

FunS

Fig.3 Antigen specificity is important for optimal anti-tumor activity.

CAR Construction : Latest CAR Construction

Fig.3 Antigen specificity is important for optimal anti-tumor activity.

The role of tumor cell targeting was tested by comparing the activity of Leu16VhY/VkZ-IL2 (DI-Leu16-IL2) and another immunocytokine with binding specificity for EGFR, a molecule expressed at only low levels of Daudi lymphoma cells. Treatments included PBS only (X, on Days 7-11); rituximab (filled diamonds, 25 mg/kg on Days 7, 9 and 11); Leu16VhY/VkZ (DI-Leu16 antibody; open diamonds, 25 mg/kg on Days 7, 9 and 11); medium dose Leu16VhY/VkZ-IL2 (DI-Leu16-IL2; filled squares, 1 mg/kg on Days 7-11); reduced dose Leu16VhY/VkZ-IL2 (DI-Leu16-IL2, open circle, 1 mg/kg on Days 7 and 10); low dose Leu16VhY/VkZ-IL2 (DI-Leu16-IL2; open squares, 0.25 mg/kg on Days 7-11); and medium dose anti-EGFR-IL2 (filled triangle, 1 mg/kg on Days 7-11).

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 (Leu-16) h(CD3ζ) CAR, pCDCAR1 (CAR-MZ017). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.